Table S1 Literature search strategy

Database	Search strategy
PubMed	((((((((Nasopharyngeal Carcinoma[MeSH Terms]) OR (Carcinoma*, Nasopharyngeal[Title/Abstract])) OR (Nasopharyngeal Carcinoma*[Title/Abstract])) OR (Nasopharyngeal cancer*[Title/Abstract])) OR (NPC[Title/Abstract])) AND ((((("recurrent"[Title/Abstract] OR "metastatic"[Title/Abstract] OR "advance*"[Title/Abstract] OR "RM"[Title/Abstract] OR "R/M"[Title/Abstract])) OR (R-M[Title/Abstract]))) OR ("recurrent or metastatic"[Title/Abstract]))) AND ("clinical trials as topic"[MeSH Terms] OR "clinical trial"[Publication Type] OR "phase III"[Title/Abstract] OR "phase 3"[Title/Abstract] OR "clinical trials"[Title/Abstract])) AND ("programmed cell death 1 receptor/antagonists and inhibitors"[MeSH Terms] OR "PD-1"[Title/Abstract] OR "PD-L1"[Title/Abstract] OR "anti-PD-1"[Title/Abstract] OR"anti-PD-L1"[Title/Abstract] OR "Immune checkpoint inhibitor"[Title/Abstract] OR "ICIs "[Title/Abstract] OR"programmed cell death 1 receptor antagonists and inhibitors"[Title/Abstract] OR "programmed cell death 1 receptor antagonist"[Title/Abstract] OR "programmed cell death 1 receptor inhibitor"[Title/Abstract] OR "Immunotherapy"[Title/Abstract] OR "chemo-immunotherapy"[Title/Abstract] OR "toripalimab"[Title/Abstract] OR "pembrolizumab"[Title/Abstract] OR "atezolizumab"[Title/Abstract] OR "durvalumab"[Title/Abstract] OR "tremelimumab"[Title/Abstract] OR "ipilimumab"[Title/Abstract] OR "camrelizumab"[Title/Abstract] OR "nivolumab"[Title/Abstract] OR "tislelizumab"[Title/Abstract] OR "sintilimab"[Title/Abstract])) NOT ("review"[Title] OR "meta"[Title] OR "meta-analysis"[Title] OR "protocol"[Title])
Embase	('programmed cell death 1 receptor/antagonists and inhibitors':ti,ab OR 'pd-1':ti,ab OR 'pd-l1':ti,ab OR 'anti-pd-1':ti,ab OR 'anti-pd-l1':ti,ab OR 'immune checkpoint inhibitor':ti,ab OR 'icis':ti,ab OR 'programmed cell death 1 receptantagonists and inhibitors':ti,ab OR 'programmed cell death 1 receptantagonist':ti,ab OR 'programmed cell death 1 receptinhibitor':ti,ab OR 'immunotherapy':ti,ab OR 'chemo-immunotherapy':ti,ab OR 'toripalimab':ti,ab OR 'pembrolizumab':ti,ab OR 'atezolizumab':ti,ab OR 'durvalumab':ti,ab OR 'tremelimumab':ti,ab OR 'ipilimumab':ti,ab OR 'camrelizumab':ti,ab OR 'nivolumab':ti,ab OR 'tislelizumab':ti,ab OR 'sintilimab':ti,ab) AND ('nasopharynx carcinoma'/exp OR 'nasopharyngeal carcinoma':ab,ti OR 'carcinoma*, nasopharyngeal':ab,ti OR 'nasopharyngeal carcinoma*':ab,ti OR 'nasopharyngeal cancer':ab,ti OR 'npc':ab,ti OR 'nasopharynx carcinoma':ab,ti) AND ('recurrent':ab,ti OR 'metastatic':ab,ti OR 'advance*':ab,ti OR 'rm':ab,ti OR 'r-m':ab,ti OR 'r/m':ab,ti OR 'recurrent or metastatic':ab,ti) AND ('trial'/exp OR 'clinical trials'/exp OR 'phase 3 clinical trial'/exp OR 'phase iii clinical trial'/exp OR 'clinical trial':exp) AND ([article]/lim OR [article in press]/lim) AND [humans]/lim
Cochrane Library	#1 MeSH descriptor: [Nasopharyngeal Carcinoma] explode all trees #2 ("Carcinoma*, Nasopharyngeal"):ti,ab,kw OR ("Nasopharyngeal Carcinoma*" OR "Nasopharyngeal cancer" OR "NPC" OR "nasopharynx carcinoma"):ti,ab,kw #3 #1 OR #2 #4 ("programmed cell death 1 receptor/antagonists and inhibitors" OR "pd-1" OR 'pd-l1' OR 'anti-pd-1' OR'immune checkpoint inhibitor' OR 'icis' OR 'programmed cell death 1 receptantagonists and inhibitors' OR 'programmed cell death 1 receptantagonist' OR 'programmed cell death 1 receptinhibitor' OR 'immunotherapy' OR 'chemo-immunotherapy' OR 'toripalimab' OR 'pembrolizumab' OR 'atezolizumab' OR 'durvalumab' OR 'tremelimumab' OR 'ipilimumab' OR 'camrelizumab' OR 'nivolumab' OR 'tislelizumab' OR 'sintilimab'):ti,ab,kw #5 ("recurrent" OR "metastatic" OR "advance*" OR "RM" OR "R/M" OR “R-M” OR "recurrent or metastatic"):ti,ab,kw #6 ("phase III" OR "phase 3"):ti,ab,kw #3 AND #4 AND #5 AND #6

https://dx.doi.org/10.21037/tcr-2025-415

Table S2 Selection criteria

Inclusion criteria
Patients were eligible for enrolment if they were aged over 18 years old and confirmed pathologically R/M NPC
The type of study were RCTs
RCTs comparing immunotherapy plus chemotherapy with placebo plus chemotherapy as first-line treatments for patients with R/M NPC
Phase III trials reporting at least one of the following clinical outcomes: ● PFS, defined as the time from randomization to disease progression or death from any cause; ● OS, defined as the time from randomization until death from any cause; ● Objective response rate (ORR), defined as the proportion of patients who achieved an objective response; ● Grade≥3 TEAEs and immune-related TEAEs (irTEAEs) which were defined and graded according to the National Cancer Institute Common Terminology Criteria for AEs.
Exclusion criteria
Cohort studies, reviews, meta-analyses, newspapers and other non-RCT studies
RCTs with ambiguous clinical outcomes;
Repeated publication with same research data
Full text of the literature was not available

https://dx.doi.org/10.21037/tcr-2025-415

Table S3 Baseline characteristics of studies included in the network meta-analysis

Study	Phase, design	Source (y)	Registered ID	Randomization	Sample Size (n), intervention arm/control arm	ECOG performance score, n (0)/n (1) (%)	Histology, n (%)	Ethnicity (%)	Age, median (range), (y)	Male/Female (%)	Intervention Arm (s)	Control Arm (s)
JUPITER-02	III, double-blind	Nature Medicine (2021) AACR (2022)	NCT03581786	1:1	146/143	Intervention Arm (43/57); Control Arm (43/57)	Non-keratinizing (99), Keratinizing (1)	Asian (100.0); Other (0)	Intervention Arm 46 (19–72); Control Arm 51 (21–72)	Intervention Arm (85/15); Control Arm (81/19)	Toripalimab (240mg) day 1, gemcitabine (1,000 mg m^{-2}) on days 1 and 8, cisplatin (80mg m^{-2}) on day1, Q3W	Placebo (240mg) day 1, gemcitabine (1,000 mg m^{-2}) on days 1 and 8, cisplatin (80mg m^{-2}) on day1, Q3W
CAPTAIN-1ST	III, double-blind	Lancet Oncol (2021)	NCT03707509	1:1	134/129	Intervention Arm (35/65); Control Arm (34/66)	Non-keratinizing (98); Keratinizing (1); Other (1)	Asian (100.0); Other (0)	Intervention Arm 52 (40–58); Control Arm 49 (40–56)	Intervention Arm (84/16); Control Arm (81/19)	Camrelizumab (200mg) day 1, gemcitabine (1,000mg m^{-2}) on days 1 and 8, cisplatin (80mg m^{-2}) on day1, Q3W	Placebo (200mg) day 1, gemcitabine (1,000 mg m^{-2}) on days 1 and 8, cisplatin (80mg m^{-2}) on day1, Q3W
RATIONALE 309	III, double-blind	Cancer Cell (2023)	NCT03924986	1:1	131/132	Intervention Arm (39/61); Control Arm (35/65)	Non-keratinizing (87); Keratinizing (7) Other (6)	Asian (100.0); Other (0)	Intervention Arm 50 (26–74); Control Arm 50 (23–73)	Intervention Arm (79/21); Control Arm (78/22)	Tislelizumab (200 mg) day 1, gemcitabine (1,000 mg m^{-2}) on days 1 and 8, cisplatin (80mg m^{-2}) on day1, Q3W	Placebo (200mg) day 1, gemcitabine (1,000 mg m^{-2}) on days 1 and 8, cisplatin (80 mg m^{-2}) on day 1, Q3W

https://dx.doi.org/10.21037/tcr-2025-415

Table S4 Summary of PFS, OS and Tumor response

STUDY	Median follow-up, (Intervention Arm/Control Arm), months	PFS			OS			Tumor response					
		Median (95% CI) (months)			Median (95% CI) (months)			CR, %		PR, %		ORR, %	
		Intervention Arm	Control Arm	HR (95% CI)	Intervention Arm	Control Arm	HR (95% CI)	Intervention Arm	Control Arm	Intervention Arm	Control Arm	Intervention Arm	Control Arm
JUPITER-02 (2022)	22.1/21.4	21.4 (11.7, NE)	8.2 (7.0, 9.8)	0.52 (0.37, 0.73)	NE (NE, NE)	NE (NE, NE)	0.59 (0.37,0.94)	26.7	13.3	52.1	53.8	78.8	67.1
JUPITER-02 (2021)	17.9/17.4	11.7 (11.0, NE)	8.0 (7.0, 9.5)	0.52 (0.36, 0.74)	NE (NE, NE)	NE (22.8, NE)	0.603 (0.364,0.997)	19.2	11.2	58.2	55.2	77.4	66.4
JUPITER-02 (2023)	36	21.4 (11.7, NE)	8.2 (7.0, 9.8)	0.52 (0.37, 0.73)	NE (38.7, NE)	33.7 (27,44.2)	0.63 (0.45, 0.89)	26.7	13.3	52.1	53.8	78.8	67.1
CAPTAIN-1ST (2021)	15.6	10.8 (8.5, 13.6)	6.9 (5.9, 7.9)	0.51 (0.37, 0.69)	NE (NE, NE)	22.6 (19.2, NE)	0.67 (0.41, 1.11)	5.2	1.6	82.8	79.1	88.1	80.6
RATIONALE 309 (2023)	15.5	9.6 (7.6, 11.7)	7.4 (5.7, 7.6)	0.50 (0.37, 0.68)	NE (23.7, NE)	23.0 (19.8, NE)	0.60 (0.35, 1.01)	16	6.8	53.4	48.5	69.5	55.3
RATIONALE 309 (2024)	NA	9.6 (7.6, 11.6)	7.4 (5.6, 7.6)	0.53 (0.39, 0.71)	45.3 (33.4, NE)	31.8 (25.0, NE)	0.73 (0.51, 1.05)	NA	NA	NA	NA	NA	NA

https://dx.doi.org/10.21037/tcr-2025-415

Table S5 TEAEs reported in at least 20% of patients in both treatment arms or large differences between arms

TEAEs	Any grade (%)				Grade≥3 (%)			
	JUPITER-02	CAPTAIN-1ST	RATIONALE 309	GP	JUPITER-02	CAPTAIN-1ST	RATIONALE 309	GP
Any TEAE	100	100	100	100	89	94	80.9	87
White blood cell count decreased	91	96	61.8	85	61.6	66	31.3	55
Neutrophil count decreased	85.6	95	60.3	82	57.5	64	27.5	55
Anemia	88.4	94	87.8	94	47.3	39	29.8	37
Nausea	69.2	70	57.3	74	1.4	4	0	2
Vomiting	67.1	56	38.9	59	2.1	7	0.8	2
Platelet count decreased	63	80	53.4	68	32.9	40	20.6	31
Decreased appetite	53.4	64	47.3	55	0.7	0	0.8	0
Constipation	39	45	34.4	41	0	0	0	0
Aspartate aminotransferase increased	37.7	25	22.1	27	1.4	3	0	1
Alanine aminotransferase increased	36.3	27	24.4	28	0.7	1	0.8	0
Fatigue/Asthenia	35.6	49	12.2	32	1.4	2	0.8	1
Pyrexia	30.8	17	21.4	15	1.4	0	0.8	0
Hypothyroidism	30.8	46	25.2	18	0	0	0.8	0
Rash	27.4	34	26	21	3.4	1	4.6	1
Hyponatremia	25.3	31	23.7	29	8.9	10	2.3	4
Hypokalemia	21.2	24	19.8	23	6.8	7	3.1	5
Blood creatinine increased	17.8	23	22.9	20	0	0.7	0	0
Hypochloremia	17.8	21	9.2	18	1.4	0.7	0	0
Lymphopenia	11	23	13.7	17	8.9	19	10.7	6
Diarrhea	30.1	19	9.9	17	2.1	1	0	0
Cough	23.3	4	18.3	12	0	0.7	0	0
Dizziness	21.2	7	13.7	17	0	0	0	1
Hypoaesthesia	NA	28	14.5	NA	NA	0	0	NA
Reactive capillary endothelial proliferation	NA	58	NA	NA	NA	0	NA	NA
Peripheral neuropathy	30.1	NA	NA	NA	0	NA	NA	NA
Musculoskeletal pain	23.3	NA	NA	NA	0	NA	NA	NA
Insomnia	19.2	NA	9.9	NA	0	NA	0	NA

https://dx.doi.org/10.21037/tcr-2025-415

Table S6 Summary of immune-related treatment-emergent adverse events occurring in at least 1% of patients

Immune-related TEAE	Any grade (%)			Grade≥3 (%)		
	JUPITER-02	CAPTAIN-1ST	RATIONALE 309	JUPITER-02	CAPTAIN-1ST	RATIONALE 309
Any immune-related TEAE	39.7	84	18.3	7.5	15	2.3
Hypothyroidism	17.8	43	13.7	0	0	0.8
Rash	8.9	25	3.8	3.4	0.7	1.5
Pruritus	6.2	13	1.5	0	0	0
Aspartate aminotransferase increased	4.8	15	NA	0	3	NA
Alanine aminotransferase increased	4.1	16	NA	0	0.7	NA
Anemia	2.1	4	NA	0.7	2	NA
Leukopenia	1.4	1	NA	0	0	NA
Neutropenia	1.4	1	NA	0	0	NA
Pneumonia	1.4	4	NA	1.4	0.7	NA
Nervous system disorders	1.4	0.7	NA	0	0.7	NA
Hyperthyroidism	2.7	NA	0.8	0	NA	0
Dermatitis	1.4	NA	NA	0	NA	NA
Blood thyroid stimulating hormone increased	4.1	NA	NA	0	NA	NA
Thrombocytopenia	2.7	NA	NA	2.1	NA	NA
Pyrexia	3.4	NA	NA	0	NA	NA
Fatigue	1.4	NA	NA	0	NA	NA
Neuropathy peripheral	1.4	NA	NA	0	NA	NA
Hematuria	1.4	NA	NA	0	NA	NA
Reactive capillary endothelial proliferation	NA	58	NA	NA	0	NA
Hypoaesthesia	NA	20	NA	NA	0	NA
Blood creatinine increased	NA	10	NA	NA	0	NA
Anti-thyroid antibody positive	NA	10	NA	NA	0	NA
Thyroglobulin decreased	NA	10	NA	NA	0	NA
Diarrhoea	NA	4	NA	NA	1	NA
White blood cell count decreased	NA	1	NA	NA	0	NA
Neutrophil count decreased	NA	1	NA	NA	0	NA
Hypertension	NA	2	NA	NA	1	NA
Myoglobin blood increased	NA	1	NA	NA	0.7	NA

https://dx.doi.org/10.21037/tcr-2025-415

Table S7 Specific medication modalities in the CEA model

Group	PFS (0-4.5 m)			PFS (4.5-28.5 m)			PFS (>28.5 m)	PD		
TorGP	Toripalimab	Day 1 240 mg	Q3W	Toripalimab	Day 1 240 mg	Q3W	NA	Capecitabine	D1-D14 1.25g/m^2	Q3W
	Gemcitabine	Day 1 & Day 8 1,000 mg/m^2	Q3W							
	Cisplatin	Day 1 80 mg/m^2	Q3W							
CamGP	Camrelizumab	Day 1 200 mg	Q3W	Camrelizumab	Day 1 200 mg	Q3W	NA	Capecitabine	D1-D14 1.25g/m^2	Q3W
	Gemcitabine	Day 1 & Day 8 1,000 mg/m^2	Q3W							
	Cisplatin	Day 1 80 mg/m^2	Q3W							
TisGP	Tislelizumab	Day 1 200 mg	Q3W	Tislelizumab	Day 1 200 mg	Q3W	NA	Capecitabine	D1-D14 1.25g/m^2	Q3W
	Gemcitabine	Day 1 & Day 8 1,000 mg/m^2	Q3W							
	Cisplatin	Day 1 80 mg/m^2	Q3W							
GP	Gemcitabine	Day 1 & Day 8 1,000 mg/m^2	Q3W	NA	NA	NA	NA	Capecitabine	D1-D14 1.25g/m^2	Q3W
	Cisplatin	Day 1 80 mg/m^2	Q3W							

https://dx.doi.org/10.21037/tcr-2025-415



Figure S1 Schoenfeld residual plots.

https://dx.doi.org/10.21037/tcr-2025-415



Figure S2 Parametric survival models.

https://dx.doi.org/10.21037/tcr-2025-415

Table S8 AIC Scores and BIC Scores for Standard Parametric Survival Model

Curves	Exponential	Weibull	Gompertz	Log-logistic	Log-normal
TorGP OS curve					
AIC	281.3634	278.5438	279.4237	*278.5391	279.732
BIC	*284.347	284.511	285.3909	284.5063	285.6992
GP OS curve					
AIC	391.7595	376.0521	380.382	375.6203	*374.5913
BIC	394.7223	381.9778	386.3077	381.546	*380.517
TorGP PFS curve					
AIC	403.977	*387.488	390.8653	388.0919	390.055
BIC	406.9606	*393.4552	396.8325	394.0591	396.0222
GP PFS curve					
AIC	554.3736	502.4287	517.7924	*498.0194	505.8609
BIC	557.3365	508.3544	523.718	*503.9451	511.7866

*, For the two results of OS-TorGP, log-Logistic is more consistent with the original curve by observing the curves.

https://dx.doi.org/10.21037/tcr-2025-415



Figure S3 Kaplan-Meier Curve Fitting and Extrapolation.

https://dx.doi.org/10.21037/tcr-2025-415

Table S9 AIC Scores for Restricted Cubic Splines Models

Curves	hazard_3	hazard_4	hazard_5	odds_3	odds_4	odds_5	normal_3	normal_4	normal_5
TorGP OS curve	284.235	286.2278	*277.6103	284.1708	285.9635	278.2098	283.9956	285.8205	-
GP OS curve	380.425	382.1105	383.0973	380.4055	382.1483	383.1068	*379.8811	381.681	382.5054
TorGP PFS curve	*393.3114	393.8526	395.5369	393.7391	394.0458	398.298	393.355	393.5319	396.0376
GP PFS curve	496.6302	497.4619	498.9211	496.7996	498.5869	496.1211	497.2883	498.6308	*495.3941

* The minimum AIC scores.

https://dx.doi.org/10.21037/tcr-2025-415



Figure S4 Flowchart of Study Selection

https://dx.doi.org/10.21037/tcr-2025-415



Figure S5 The quality of the included literature evaluated by the RoB2.

https://dx.doi.org/10.21037/tcr-2025-415

Table S10 Safety data summarized in three RCTs

Study	JUPITER-02		CAPTAIN-1ST		Rationale-309	
	Toripalimab + GP (n= 146)	Placebo + GP n= 143)	Camrelizumab+GP (n=134)	Placebo + GP (n= 129)	Tislelizumab+GP (n=131)	Placebo+GP (n=132)
TEAE	146 (100.0)	143 (100.0)	134 (100)	129 (100)	131 (100.0)	131 (99.2)
≥Grade 3 TEAE	130 (89.0)	128 (89.5)	126 (94)	117 (91)	106 (80.9)	108 (81.8)
Serious TEAE	60 (41.1)	62 (43.4)	48 (36)	38 (29)	36 (27.5)	44 (33.3)
≥Grade 3 Serious TEAE	NA	NA	NA	NA	30 (22.9)	35 (26.5)
TEAE leading to death	4 (2.7)	4 (2.8)	5 (4)	1 (<1)	5 (3.8)	2 (1.5)
TEAE leading to permanent discontinuation of all treatments	11 (7.5)	7 (4.9)	12 (9)	6 (5)	2 (1.5)	3 (2.3)
Immune-mediated TEAE	58 (39.7)	27 (18.9)	112 (84)	65 (50%)	24 (18.3)	NA
≥Grade 3 Immune-mediated TEAE	11 (7.5)	1 (0.7)	20 (15)	NA	3 (2.3)	NA

https://dx.doi.org/10.21037/tcr-2025-415



Figure S6 Radar plot ranked according to SUCRA.

https://dx.doi.org/10.21037/tcr-2025-415



Figure S7 Trajectory plots and density plots. (A) Trajectory and density plots of PFS. (B) Trajectory and density plots of OS. (C) Trajectory and density plots of Grade≥3 TEAEs. (D) Trajectory and density plots of ORR.

https://dx.doi.org/10.21037/tcr-2025-415



Figure S8 The Brooks-Gelman-Rubin diagnostic.

https://dx.doi.org/10.21037/tcr-2025-415



Figure S9 K-M and parametric survival distributions for OS and PFS. (A) Tor-GP group. (B) GP group.

https://dx.doi.org/10.21037/tcr-2025-415





Figure S10 Tornado diagrams.

https://dx.doi.org/10.21037/tcr-2025-415

Table S11 Scenario analysis for second-line therapy

Strategies	Total cost ($)	LYs	QALYs	ICER (vs. GP) ($/QALY)	ICER (vs. Camrelizumab+GP) ($/QALY)	ICER (vs. Toripalimab+GP) ($/QALY)	WTP ($/QALY)
Base-case analysis for Standard Parametric Survival Model of Gemcitabine							
GP	25,152	3.04	1.68	-	-	-	40,354.20
Camrelizumab+GP	38,797	3.92	2.18	27,371	-	-	
Toripalimab+GP	38,146	4.11	2.28	21,916	-6,895	-	
Tislelizumab+GP	39,934	4.15	2.30	23,917	9,515	71,058	
Base-case analysis for Restricted Cubic Splines Model of Gemcitabine							
GP	22,927	2.73	1.53	-	-	-	40,354.20
Camrelizumab+GP	30,956	2.83	1.61	89,930	-	-	
Toripalimab+GP	29,676	2.93	1.67	48,253	-25,319	-	
Tislelizumab+GP	31,469	2.97	1.69	52,323	6,931	71,058	

https://dx.doi.org/10.21037/tcr-2025-415

Base-case analysis for Mixture Cure Model of Gemcitabine							
GP	25,176	3.05	1.70	-	-	-	40,354.20
Camrelizumab+GP	55,412	6.23	3.38	17,920	-	-	
Toripalimab+GP	54,332	6.36	3.45	16,646	-16,816	-	
Tislelizumab+GP	55,963	6.38	3.46	17,440	7,066	118,822	
Base-case analysis for Standard Parametric Survival Model of Docetaxel							
GP	21,231	3.04	1.68	-	-	-	40,354.20
Camrelizumab+GP	33,833	3.92	2.18	25,280	-	-	
Toripalimab+GP	32,819	4.11	2.28	19,546	-10,742	-	
Tislelizumab+GP	34,580	4.15	2.30	21,599	6,247	69,964	
Base-case analysis for Restricted Cubic Splines Model of Docetaxel							
GP	19,548	2.73	1.53	-	-	-	40,354.20
Camrelizumab+GP	27,949	2.83	1.61	94,093	-	-	
Toripalimab+GP	26,456	2.93	1.67	49,387	-29,532	-	
Tislelizumab+GP	28,225	2.97	1.69	53,151	3,732	75,652	

https://dx.doi.org/10.21037/tcr-2025-415

Base-case analysis for Mixture Cure Model of Docetaxel							
GP	21,266	3.05	1.70	-	-	-	40,354.20
Camrelizumab+GP	46,387	6.23	3.38	14,889	-	-	
Toripalimab+GP	45,047	6.36	3.45	13,578	-20,865	-	
Tislelizumab+GP	46,688	6.38	3.46	14,402	3,862	119,577	

GP, gemcitabine and cisplatin; ICER, incremental cost-effectiveness.

https://dx.doi.org/10.21037/tcr-2025-415